These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 27059672)
61. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries. Grant S; Lutz EM; McPhaden AR; Wadsworth RM J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462 [TBL] [Abstract][Full Text] [Related]
62. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats. Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946 [TBL] [Abstract][Full Text] [Related]
63. Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata. Laufer Britva R; Keren A; Bertolini M; Ullmann Y; Paus R; Gilhar A Elife; 2023 Mar; 12():. PubMed ID: 36930216 [TBL] [Abstract][Full Text] [Related]
64. Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells. Jimeno R; Leceta J; Martínez C; Gutiérrez-Cañas I; Carrión M; Pérez-García S; Garín M; Mellado M; Gomariz RP; Juarranz Y J Mol Neurosci; 2014 Nov; 54(3):512-25. PubMed ID: 24805298 [TBL] [Abstract][Full Text] [Related]
65. Analysing the dynamics of a model for alopecia areata as an autoimmune disorder of hair follicle cycling. Dobreva A; Paus R; Cogan NG Math Med Biol; 2018 Sep; 35(3):387-407. PubMed ID: 28992198 [TBL] [Abstract][Full Text] [Related]
66. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Herbst V; Zöller M; Kissling S; Wenzel E; Stutz N; Freyschmidt-Paul P Eur J Dermatol; 2006; 16(5):537-42. PubMed ID: 17101475 [TBL] [Abstract][Full Text] [Related]
67. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis. Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358 [TBL] [Abstract][Full Text] [Related]
68. Deciphering the Complex Immunopathogenesis of Alopecia Areata. Šutić Udović I; Hlača N; Massari LP; Brajac I; Kaštelan M; Vičić M Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891839 [TBL] [Abstract][Full Text] [Related]
69. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743 [TBL] [Abstract][Full Text] [Related]
70. A natural canine homologue of alopecia areata in humans. Tobin DJ; Gardner SH; Luther PB; Dunston SM; Lindsey NJ; Olivry T Br J Dermatol; 2003 Nov; 149(5):938-50. PubMed ID: 14632797 [TBL] [Abstract][Full Text] [Related]
71. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Reubi JC; Läderach U; Waser B; Gebbers JO; Robberecht P; Laissue JA Cancer Res; 2000 Jun; 60(11):3105-12. PubMed ID: 10850463 [TBL] [Abstract][Full Text] [Related]
72. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Couvineau A; Laburthe M Br J Pharmacol; 2012 May; 166(1):42-50. PubMed ID: 21951273 [TBL] [Abstract][Full Text] [Related]
73. AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice. Maglakelidze N; Gao T; Feehan RP; Hobbs RP J Invest Dermatol; 2023 Apr; 143(4):578-587.e3. PubMed ID: 36270546 [TBL] [Abstract][Full Text] [Related]
74. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. Ito T; Hashizume H; Shimauchi T; Funakoshi A; Ito N; Fukamizu H; Takigawa M; Tokura Y J Dermatol Sci; 2013 Feb; 69(2):140-7. PubMed ID: 23312578 [TBL] [Abstract][Full Text] [Related]
76. Potential immunomodulatory role of VIP in the implantation sites of prediabetic nonobese diabetic mice. Roca V; Calafat M; Larocca L; Ramhorst R; Farina M; Franchi AM; Leirós CP Reproduction; 2009 Oct; 138(4):733-42. PubMed ID: 19633131 [TBL] [Abstract][Full Text] [Related]
77. The hair follicle and immune privilege. Paus R; Ito N; Takigawa M; Ito T J Investig Dermatol Symp Proc; 2003 Oct; 8(2):188-94. PubMed ID: 14582671 [TBL] [Abstract][Full Text] [Related]
78. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells. Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170 [TBL] [Abstract][Full Text] [Related]
79. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects. Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439 [TBL] [Abstract][Full Text] [Related]
80. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Ito T; Ito N; Bettermann A; Tokura Y; Takigawa M; Paus R Am J Pathol; 2004 Feb; 164(2):623-34. PubMed ID: 14742267 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]